Advisory Committee Review Will Test Whether One Trial Will Do The Trick For Bristol's Ipilimumab
This article was originally published in The Pink Sheet Daily
Executive Summary
Panelists may want to wait for results from a second Phase III trial and, given severe side effects, are likely to want a robust risk management plan.
You may also be interested in...
Yervoy Cuts To The Head Of The Line: Ipilimumab Has Unrestricted Label
Bristol-Myers Squibb's immunotherapy Yervoy (ipilimumab) will enter the market positioned for wide use, with a broad label for its approval for metastatic melanoma and positive Phase III results for front-line patients.
Yervoy Cuts To The Head Of The Line: Ipilimumab Has Unrestricted Label
Bristol-Myers Squibb's immunotherapy Yervoy (ipilimumab) will enter the market positioned for wide use, with a broad label for its approval for metastatic melanoma and positive Phase III results for front-line patients.
Hopes Rise For Approval Of Melanoma Drug Ipilimumab, With Positive Front-line Results
As Bristol-Myers' ipilimumab nears its March 26 PDUFA date for second-line melanoma, drug demonstrates good results in front-line study. Will the data sway regulators?